Review Papers Against Their Own Results

 Long Explanation Copied

Mechanism the Paper Establishes

Jimenez-Moreno et al. (bioRxiv, Nov 2025) identify a new, PKA-independent arm of the cAMP pathway: cytoplasmic TurboID proximity proteomics across five ER-phagy receptors ranked PRKAR1A as the strongest activator of FAM134B/C flux, and CRISPR knockout of Prkar1a suppressed basal (Atg7-dependent) FAM134B/C flux while forskolin (FSK) still activated flux in control cells but was blunted by Prkar1a loss — ruling out canonical PKACAT suppression as the mechanism Main preprint: PRKAR1A is cAMP-responsive FAM134B/C activator. Molecularly, an amphipathic helix at FAM134B residues 385-421 (mapped to 392-408; I400/I417 critical) binds a hydrophobic pocket in the PRKAR1A N-terminal dimerization domain, supported by recombinant in vitro binding, AlphaFold3 modelling and a FoldX ΔΔG of 1.69 kcal/mol for the I400R-disrupting mutation Structural mapping of FAM134B amphipathic helix to PRKAR1A pocket.

FRAP shows PRKAR1A in FSK-induced foci recovers rapidly (liquid-like) while FAM134B-EGFP does not (membrane-immobilised); SoRA and CLEM resolve these as irregular, partially non-membrane-delimited condensates making extensive ER contacts with embedded LAMP1+ lysosomes — framed as "degradation hubs" FRAP and CLEM define ER-contacting PRKAR1A condensates. Condensate disruption (1,6-hexanediol, 2.5%) or ΔIDR PRKAR1A ablates FAM134B-LC3B clustering, while mtPS (PKACAT-binding deficient) PRKAR1A rescues it, consolidating kinase independence Condensate dependence and PKACAT independence of FAM134B clustering.

RhoA Sequestration and Physiology

FSK-shifted FAM134B proximity proteomes enrich Rho-family Reactome signatures; FAM134B/C co-IP binds inactive RhoA (T19N) selectively over active G14V, and T19N RhoA is preferentially trafficked to lysosomes in an FSK-, Fam134b/c- and Prkar1a-dependent manner; downstream P-MLC2 suppression is reversed by Y27632 in knockouts RhoA lysosomal sequestration via FAM134B condensate hubs. Physiologically, the axis drives cAMP-dependent protrusion, reduced collective wound closure, and a collective-to-single-cell invasion switch in 3D collagen spheroids (rescue requires I400 and LIR); epinephrine reproduces the switch Physiological morphology and invasion-mode switch requiring the axis. This complements known condensate biology of cAMP-bound PRKAR1A Prior PRKAR1A condensate discovery (Cell 2020) and connects to parallel findings that ER-phagy receptors regulate non-ER-proteostasis clients (e.g., SERCA1 in statin myopathy Parallel FAM134B client-expansion evidence (statin myopathy)).

Schematic network of the sourced mechanism: cAMP → PRKAR1A condensates → FAM134B/C clustering with LC3B → lysosomal degradation hub co-sequestering RhoA → reduced ROCK/P-MLC2 → morphology/invasion switch (per the preprint and Cell 2020 condensate work).

Blind Spots and What Would Change the Verdict

The authors themselves flag overexpression of tagged baits, non-specific 1,6-hexanediol, and the largely correlative link between condensates and flux Author-acknowledged limitations and blindspots. Additional BGPT-noted caveats: almost all mechanistics use one murine KPC PDAC line (HEK293FT only for co-IP), so cell-type generality is asserted, not shown; RhoA itself was not confidently quantifiable in the proteome — the RhoA connection rests on pathway enrichment of its interactors plus co-IP; an alternative explanation (RhoA as indirect passenger of lysosome-delivered membranes) is not formally excluded. Replication at endogenous expression levels, a second cancer type, or in vivo metastasis data would falsify or strengthen the model. Funding: CRUK Senior Fellowship C20685/A29576; authors declare no competing interests Funding, conflicts, and model provenance.

 BGPT Paper Review

Study Novelty

First demonstration that a cytoplasmic signaling condensate (cAMP-bound PRKAR1A) physically contacts the ER to activate ER-phagy and co-sequester RhoA — a genuinely new interorganellar contact class and a new non-canonical role for both PRKAR1A and FAM134B/C cytoplasmic domains.

Scientific Quality

Dense multi-modal validation (proteomics, CRISPR screens, FRAP, SoRA, CLEM, recombinant binding, structural modelling, rescue mutants, 3D invasion). Weaknesses: single murine PDAC line for most mechanistics, hexanediol non-specificity, RhoA not directly quantified in proteomics, no in vivo data.

Study Generality

The mechanistic principle (condensate-ER contact degradation hubs coordinating signaling-protein turnover) likely generalizes, but evidence is confined to one PDAC model; author-inferred relevance to neurogenesis proteomics is speculative.

Study Usefulness

Provides a testable axis (PRKAR1A-FAM134B/C-RhoA) linking cAMP signaling, ER-phagy, cytoskeleton, and cancer invasion plasticity — actionable for invasion-mode biology and PRKAR1A/Carney-complex disease contexts.

Study Reproducibility

Extensive Key Resource Table, gRNA/primers/plasmid lists, n values, and deposited MS data/AlphaFold models; however exact repository accession numbers were not extractable from the provided text.

Explanatory Depth

Causal chain resolved from atomic-level binding pocket (AlphaFold3/FoldX) through condensate biophysics (FRAP) to cell behaviour (invasion mode), with clean epistatic logic excluding PKACAT via both genetics and pharmacology.